checkAd

Teva Announces Appointment of Richard Francis as President and CEO

Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”) (NYSE and TASE: TEVA), today announced that the Company’s Board of Directors has appointed Richard Francis as President and Chief Executive Officer, effective January 1, 2023. In order to facilitate an orderly transition, Kåre Schultz and the Teva Board of Directors have mutually agreed that Mr. Schultz will retire from his current position as Chief Executive Officer, effective December 31, 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221121005362/en/

Mr. Francis is a seasoned pharmaceutical executive bringing more than two and a half decades of experience to Teva, including five years as Chief Executive Officer of Sandoz and a member of the Novartis Executive Team. Prior to his role at Sandoz, Mr. Francis was a senior executive at Biogen for 13 years where he held a number of senior roles, including leading the U.S. business. He also oversaw the successful launch of Tecfidera in 2013. Mr. Francis is currently the CEO of Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, and CEO of Forcefield Therapeutics, a pioneer of best-in-class therapeutics to protect heart function. He is also an operating partner for Syncona Investment Management Limited.

“It has been a great privilege to serve Teva as its CEO since 2017, and to work with our dedicated and talented team to improve the lives of patients,” said Mr. Schultz. “We have positioned Teva as a leader in both our specialty and generics businesses, built a strong financial and operational foundation and enhanced our portfolio and pipeline. This is the right time for a transition, and Richard’s proven track record in the industry makes him the right person to serve as Teva’s next CEO.”

“On behalf of the entire Board, I would like to thank Kåre for his dedication and contributions to Teva over the last five years,” said Dr. Sol J. Barer, Chairman of Teva’s Board of Directors. “Under Kåre’s leadership, we have stabilized the business and undergone a significant operational transformation across our international footprint. The Company is now well positioned for an exciting future and, by leveraging Richard’s compelling track record of growing businesses in the life sciences, biologics and generic drug sectors, his entrepreneurial and pragmatic leadership style and emphasis on a collaborative and innovative culture, the Board and I are confident that Teva will build on this solid foundation. As a global enterprise, we look forward to furthering our mission to provide much needed medicines to even more patients around the world under Richard’s leadership. The Board is delighted to have found the ideal leader for the next phase in Teva’s exciting journey to return to growth and leadership.”

Seite 1 von 4


Diskussion: Teva


0 Kommentare
Nachrichtenquelle: Business Wire (engl.)
 |  845   |   |   

Schreibe Deinen Kommentar

Disclaimer

Teva Announces Appointment of Richard Francis as President and CEO Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”) (NYSE and TASE: TEVA), today announced that the Company’s Board of Directors has appointed Richard Francis as President and Chief Executive Officer, effective January 1, 2023. In order to …

Nachrichten des Autors

308 Leser
212 Leser
192 Leser
180 Leser
172 Leser
172 Leser
168 Leser
164 Leser
152 Leser
148 Leser
1716 Leser
568 Leser
468 Leser
456 Leser
444 Leser
412 Leser
404 Leser
396 Leser
380 Leser
372 Leser
3236 Leser
2100 Leser
1716 Leser
1604 Leser
1388 Leser
1188 Leser
1168 Leser
1148 Leser
1108 Leser
1060 Leser
7528 Leser
3236 Leser
3069 Leser
2934 Leser
2497 Leser
2428 Leser
2370 Leser
2169 Leser
2106 Leser
2100 Leser